![B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera | Journal of Translational Medicine | Full Text B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera | Journal of Translational Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12967-015-0706-7/MediaObjects/12967_2015_706_Fig1_HTML.gif)
B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera | Journal of Translational Medicine | Full Text
Assembled light and heavy chain sequences of infliximab based on data... | Download Scientific Diagram
![Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering | SpringerLink Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00216-022-04396-7/MediaObjects/216_2022_4396_Figa_HTML.png)
Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering | SpringerLink
![Pharmacogenomics of etanercept, infliximab, adalimumab and methotrexate in rheumatoid arthritis. A structured review Pharmacogenomics of etanercept, infliximab, adalimumab and methotrexate in rheumatoid arthritis. A structured review](http://www.scielo.org.co/img/revistas/rcre/v25n1//0121-8123-rcre-25-01-22-gf2.jpg)
Pharmacogenomics of etanercept, infliximab, adalimumab and methotrexate in rheumatoid arthritis. A structured review
![Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab - ScienceDirect Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0021925819546087-gr2.jpg)
Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab - ScienceDirect
![Quantification of Infliximab in Human Serum by LC-MS/MS Using A Full-Length Stable Isotope Labeled Internal Standard Quantification of Infliximab in Human Serum by LC-MS/MS Using A Full-Length Stable Isotope Labeled Internal Standard](https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/marketing/global/images/technical-documents/articles/protein-biology/protein-mass-spectrometry/sec-ms-analysis/sec-ms-analysis.jpg)
Quantification of Infliximab in Human Serum by LC-MS/MS Using A Full-Length Stable Isotope Labeled Internal Standard
![Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/2100159013/2079503286/gr1.gif)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet
![Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study - Chanchlani - Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study - Chanchlani -](https://onlinelibrary.wiley.com/cms/asset/c7653e9e-9067-43a3-88ea-b7e07a110d3b/apt17170-fig-0003-m.jpg)
Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study - Chanchlani -
![Figure 5 from Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases | Semantic Scholar Figure 5 from Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/4efd15df89afa4c8412e86f40556008f96348aed/8-Figure5-1.png)
Figure 5 from Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases | Semantic Scholar
![PDF] Exploring the Binding Sites of Anti-Infliximab Antibodies in Pediatric Patients With Rheumatic Diseases Treated With Infliximab | Semantic Scholar PDF] Exploring the Binding Sites of Anti-Infliximab Antibodies in Pediatric Patients With Rheumatic Diseases Treated With Infliximab | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b67383e64c8ddbabb946caee2bcc8a7e14c32328/2-Table1-1.png)
PDF] Exploring the Binding Sites of Anti-Infliximab Antibodies in Pediatric Patients With Rheumatic Diseases Treated With Infliximab | Semantic Scholar
![Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease - Ibrahim K Nahar, Kam Shojania, Carlo A Marra, Abul H Alamgir, Aslam H Anis, 2003 Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease - Ibrahim K Nahar, Kam Shojania, Carlo A Marra, Abul H Alamgir, Aslam H Anis, 2003](https://journals.sagepub.com/cms/10.1345/aph.1C039/asset/images/large/10.1345_aph.1c039-fig1.jpeg)
Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease - Ibrahim K Nahar, Kam Shojania, Carlo A Marra, Abul H Alamgir, Aslam H Anis, 2003
![Development of a Hybrid Immunoaffinity-LC-MS/MS Method for the Quantification of Active Biotherapeutics Targeting TNF-α in Serum | Waters Development of a Hybrid Immunoaffinity-LC-MS/MS Method for the Quantification of Active Biotherapeutics Targeting TNF-α in Serum | Waters](https://www.waters.com/content/dam/waters/en/app-notes/2018/720006317/720006317en-f3-rep-chromatograms-infliximab.jpg.82.1024.resize/img.jpg)
Development of a Hybrid Immunoaffinity-LC-MS/MS Method for the Quantification of Active Biotherapeutics Targeting TNF-α in Serum | Waters
Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases
![Quantification of Infliximab in Human Serum by LC-MS/MS Using A Full-Length Stable Isotope Labeled Internal Standard Quantification of Infliximab in Human Serum by LC-MS/MS Using A Full-Length Stable Isotope Labeled Internal Standard](https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/marketing/global/images/technical-documents/articles/protein-biology/protein-mass-spectrometry/isotopic-incorporation/isotopic-incorporation.jpg)
Quantification of Infliximab in Human Serum by LC-MS/MS Using A Full-Length Stable Isotope Labeled Internal Standard
![Frontiers | Advanced assessment through intact glycopeptide analysis of Infliximab's biologics and biosimilar Frontiers | Advanced assessment through intact glycopeptide analysis of Infliximab's biologics and biosimilar](https://www.frontiersin.org/files/Articles/1006866/fmolb-09-1006866-HTML/image_m/fmolb-09-1006866-g001.jpg)
Frontiers | Advanced assessment through intact glycopeptide analysis of Infliximab's biologics and biosimilar
![The amino acid sequences of abatacept, alefacept, etanercept, and H... | Download Scientific Diagram The amino acid sequences of abatacept, alefacept, etanercept, and H... | Download Scientific Diagram](https://www.researchgate.net/publication/41056286/figure/fig5/AS:661274459394049@1534671525467/The-amino-acid-sequences-of-abatacept-alefacept-etanercept-and-H-chains-of-adalimumab.png)